A Randomized First-in-human Study of a Novel Growth Hormone Receptor Peptide Antagonist ALXN2420 in Healthy Subjects.
A new injectable hormone blocker shows promise as a safer alternative to current acromegaly treatment, advancing care for this rare growth disorder.
This randomized FIH study of ALXN2420 evaluated a novel peptide antagonist of the growth hormone receptor designed to improve on pegvisomant's limitations (weekly SC injection, hepatotoxicity risk), demonstrating favorable pharmacokinetics and dose-dependent GH axis suppression in healthy volunteers. Results provide the initial safety and PK/PD basis for advancing ALXN2420 into patient studies for acromegaly and potentially other conditions of GH excess, which have significant unmet need.
What the study was
- Study design
- Phase I Randomized First-in-Human Study
- Population
- Healthy adult subjects in FIH dose-escalation study
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- European Journal of Endocrinology
Why it surfaced
FIH data for a novel GH receptor peptide antagonist for acromegaly (rare disease, high unmet need); new mechanism class vs. pegvisomant with potentially improved administration.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.